The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

Item
http://www.wikidata.org/entity/Q38403573
Alleviating anemia and thrombocytopenia in myelofibrosis patients.Safety considerations when treating myelofibrosis.Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trialIdentification of AIM2 as a downstream target of JAK2V617F.Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.Ruxolitinib dose management as a key to long-term treatment success.Myelofibrosis: an update on drug therapy in 2016.Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidenceA spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.Recommendations on the use of ruxolitinib for the treatment of myelofibrosis.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
P2860

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

Item
http://www.wikidata.org/entity/Q38403573
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The use of erythropoiesis-stim ...... he treatment of myelofibrosis.
@en
type
label
The use of erythropoiesis-stim ...... he treatment of myelofibrosis.
@en
prefLabel
The use of erythropoiesis-stim ...... he treatment of myelofibrosis.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P932
P356
P1433
P1476
The use of erythropoiesis-stim ...... he treatment of myelofibrosis.
@en
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P932